EDF Ventures
About Us The Team Portfolio News & Events Limited Partners Contact

Press Coverage
Media Kit
News Archive
December 01, 2005

Brent Atkinson, Ph.D. Appointed Vice President, Product Development Company Relocates to Expanded Facilities in Rockville, MD.

ROCKVILLE, Maryland -- (December 01, 2005) -- BioSET, Inc. announced today the expansion of its senior management team with the appointment of Brent L. Atkinson as Vice President of Product Development.

Dr. Atkinson will be responsible for the planning and direction of the company's product development initiatives and the effective execution of pre-clinical and clinical activities as the company pursues commercialization of various medical devices incorporating its proprietary synthetic peptides. "BioSET has an impressive pipeline of new products and I am excited to join the talented team of professionals here," Brent said today.

Dr. Atkinson has an extensive background in device/drug combination products, including growth factors for tissue repair. Most recently he served as Director, R&D for Friadent Ceremed, a Division of Dentsply, Inc., where he led that company's worldwide efforts in biomedical product development and clinical study strategy. He previously worked in a similar role with Sulzer Biologics prior to its sale to Zimmer in 2001. Dr. Atkinson holds a Doctorate in Molecular Biology from Columbia University and a Bachelor of Science degree in Genetics from the University of California, Davis.

"We are pleased and fortunate to be able to add an executive with Brent's proven skills and capabilities to our team here at BioSET," said Tom Roueche, President & CEO of BioSET. "His background in biologics, growth factors and the development, regulatory approval and commercialization of combination products will be key contributors to our successful growth." Dr. Atkinson and his family will relocate to Maryland from Colorado.

Separately, the company announced its relocation into new facilities in Montgomery County, Maryland. "We are pleased and excited to announce the company's move into its recently completed lab and office space," commented Mr. Roueche. "Our tenure in the Technology Advancement Program at College Park, MD has enabled our company to develop our technology and mature our business sufficiently to require permanent facilities. Our new location is in the heart of the I-270 Innovation and Technology corridor of Rockville, Maryland, home to some of the most recognized leaders in biotechnology today, as well as numerous promising new technologies of tomorrow. We look forward to continuing our growth in one of the country's best locations for innovation and technology development."

"Maryland has one of the most supportive environments in the world for life sciences, biotechnology and vaccine research firms," said Maryland Business and Economic Development Secretary Aris Melissaratos. "By investing in and supporting technology and technology based companies such as BioSET through the initial stages of research and development, we are ensuring that Maryland's technology companies continue to grow, bring their products to the global marketplace and provide jobs to their communities."

"We are extremely pleased to welcome BioSET Inc. to Montgomery County," said County Executive Douglas M. Duncan. "This innovative company will fit in perfectly with our dynamic high tech business community and I am confident BioSET will flourish here in the County. We look forward to working with them in the future as they expand and bring even more high quality jobs to Montgomery County and Maryland."

The company's new contact information is:

Biosurface Engineering Technologies, Inc. (BioSET)
9430 Key West Avenue, Suite 220
Rockville, MD 20850

Phone: 301.795.6000
Fax: 301.340.7801

About BioSurface Technologies, Inc.
BioSET., is a private, development stage, company focused on incorporating its proprietary therapeutic peptides with medical devices to improve product performance, safety and patient well being. BioSET's synthetic peptides for tissue regeneration continue to show promising results in studies for the treatment of musculoskeletal, vascular and chronic wound diseases. The company intends to capitalize on the growing trend toward drug/device combination products and seeks to offer their novel peptides and methods of delivery to industry partners. For more information, please visit BioSET's website at: www.biosetinc.com.

Tom Roueche

< Back to News Archive

Terms  |  Privacy